Advancing stem cell therapy from bench to bedside: lessons from drug therapies

Journal of Translational Medicine

Noor Hayaty Abu Kasim¹  Thamil Selvee Ramasamy²  Thekkeparambil Chandrabose Srijaya¹ 

[1] Department of Restorative Dentistry, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia;Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

关键词: Stem cell migration;    Stem cell homing;    ¿Off-the-shelf¿ stem cell product;    Mesenchymal stem cells;    Induced pluripotent stem cells;    Drug therapy;    Cell therapy;   

Others  :  1148223
DOI  :  10.1186/s12967-014-0243-9

 received in 2014-03-22, accepted in 2014-08-26,  发布年份 2014

【 摘 要 】

The inadequacy of existing therapeutic tools together with the paucity of organ donors have always led medical researchers to innovate the current treatment methods or to discover new ways to cure disease. Emergence of cell-based therapies has provided a new framework through which it has given the human world a new hope. Though relatively a new concept, the pace of advancement clearly reveals the significant role that stem cells will ultimately play in the near future. However, there are numerous uncertainties that are prevailing against the present setting of clinical trials related to stem cells: like the best route of cell administration, appropriate dosage, duration and several other applications. A better knowledge of these factors can substantially improve the effectiveness of disease cure or organ repair using this latest therapeutic tool. From a certain perspective, it could be argued that by considering certain proven clinical concepts and experience from synthetic drug system, we could improve the overall efficacy of cell-based therapies. In the past, studies on synthetic drug therapies and their clinical trials have shown that all the aforementioned factors have critical ascendancy over its therapeutic outcomes. Therefore, based on the knowledge gained from synthetic drug delivery systems, we hypothesize that by employing many of the clinical approaches from synthetic drug therapies to this new regenerative therapeutic tool, the efficacy of stem cell-based therapies can also be improved.

【 授权许可】

   
2014 Srijaya et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Wang S, Qu X, Zhao RC: Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012, 5:19.
• [2]Picanc¸o-Castro V, Moreira LF, Kashima S, Covas DT: Can pluripotent stem cells be used in cell-based therapy? Cell Reprogram 2014, 16(2):98-107.
• [3]Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2:1366-1369.
• [4]Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
• [5]Syková E, Homola A, Mazanec R, Lachmann H, Konrádová SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006, 15(Suppl 8¿9):675-687.
• [6]Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC: Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 2011, 70(Suppl 1):59-69.
• [7]Takami T, Terai S, Sakaida I: Advanced therapies using autologous bone marrow cells for chronic liver disease. Discov Med 2012, 14(Suppl 74):7-12.
• [8]Trounson A, Thakar RG, Lomax G, Gibbons D: Clinical trials for stem cell therapies. BMC Med 2011, 9:46-52.
• [9]Sagar J, Chaib B, Sales K, Winslet M, Seifalian A: Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 2007, 7:9.
• [10]Sales KM, Winslet MC, Seifalian AM: Stem cells and cancer: an overview. Stem Cell Rev 2007, 3:249-255.
• [11]Hess DC, Borlongan CV: Stem cells and neurological diseases. Cell Prolif 2008, 41:94-114.
• [12]Van Laar JM, Tyndall A: Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45:1187-1193.
• [13]Pellegrini G, De Luca M, Arsenijevic Y: Towards therapeutic application of ocular stem cells. Semin Cell Dev Biol 2007, 18:805-818.
• [14]Cha J, Falanga V: Stem cells in cutaneous wound healing. Clin Dermatol 2007, 25:73-78.
• [15]Strauer BE, Brehm M, Schannwell CM: The therapeutic potential of stem cells in heart disease. Cell Prolif 2008, 41:126-145.
• [16]Wang Z, Lu H, Wang YC, Cong XQ: Human embryonic stem cells and liver diseases: from basic research to future clinical application. J Dig Dis 2008, 9:14-19.
• [17]Schulze M, Fändrich F, Ungefroren H, Kremer B: Adult stem cells perspectives in treatment of metabolic diseases. Acta Gastroenterol Belg 2005, 68:461-465.
• [18]Coutts M, Keirstead HS: Stem cells for the treatment of spinal cord injury. Exp Neurol 2008, 209:368-377.
• [19]Tseng SS, Lee MA, Reddi AH: Nonunions and the potential of stem cells in fracture- healing. J Bone Joint Surg Am 2008, 90:92-98.
• [20]Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR: Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am 2009, 91:1073-1083.
• [21]Hope K, Bhatia M: Clonal interrogation of stem cells. Nat Meth Suppl 2011, 8(Suppl 4):S36-S40.
• [22]Cahan P, Daley GQ: Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol 2013, 14:357-368.
• [23]Kuchina A, Espinar L, Garcia-Ojalvo J, Suel GM: Reversible and noisy progression towards a commitment point enables adaptable and reliable cellular decision-making. PLoS Comput Biol 2011, 7:e1002273.
• [24]Ebben JD, Zorniak M, Clark PA, Kuo JS: Introduction to induced pluripotent stem cells: advancing the potential for personalized medicine. World Neurosurg 2011, 76(Suppl 3¿4):270-275.
• [25][http://www.sciencedaily.com/releases/2012/11/121126151021.htm] webcite Science Daily. []
• [26]Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L: Research targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J of Ovarian Res 2010, 3:12.
• [27]Ansboro S, Greiser U, Barry F, Murphy M: Strategies for improvement of therapeutic cells: implications for tissue repair. Eur Cells Mater 2012, 23:310-319.
• [28]Kean TJ, Duesler L, Young RG, Dadabayev A, Olenyik A, Penn M, Wagner J, Fink DJ, Caplan AI, Dennis JE: Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J Drug Target 2012, 20(Suppl 1):23-32.
• [29]Resina S, Prevot P, Thierry AR: Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy. PLoS One 2009, 4(Suppl 6):e6058.
• [30]Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochem 1997, 7:36(1):66-75.
• [31]Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J: Gene therapy. Handb Clin Neurol 2012, 104:331-338.
• [32]Burks SR, Ziadloo A, Kim SJ, Nguyen BA, Frank JA: Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications. Stem Cells 2013, 31(Suppl 11):2551-2560.
• [33]Laflamme MA, Zbinden S, Epstein SE, Murry CE: Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol 2007, 2:307-339.
• [34]Vaneycken I, D¿huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T: Immuno-imaging using nanobodies. Curr Opin Biotech 2011, 22:877-881.
• [35]Sarkar D, Spencer A, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R, Kumar S, Karnik R, Lin CP, Karp JM: Engineered cell homing. Blood 2011, 118:e184-e191.
• [36]Smart N, Riley PR: The stem cell movement. Circul Res 2008, 102:1155-1168.
• [37]Zhang JJ: Mechanisms of cell therapy for clinical investigations. an urgent need for large-animal models. Circul 2013, 128:92-94.
• [38]Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circul Res 2008, 103:1204-1219.
• [39]Meirelles LDS, Fontes AM, Covas DT, Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
• [40]Drukker M, Tang C, Ardehali R, Rinkevich Y, Seita J, Lee AS, Mosley AR, Weissman IL, Soen Y: Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells. Nat Biotech 2012, 30(Suppl 6):531-544.
• [41]Wolff SN: Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transpl 2002, 29:545-552.
• [42]Zakrzewski JL: Graft failure in allogeneic haematopoietic stem cell transplantation for non-malignant disorders: basics and perspectives. Comp Clin Path 2003, 12(Suppl 1):57-59.
• [43]Mattsson J, Ringdén O, Storb R: Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 4(Suppl 1):165-170.
• [44]Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, Ringden O: Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl 2013, 48(Suppl 4):616.
• [45]Locatelli F, Lucarelli B, Merli P: Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother 2014, 15(Suppl 1):23-36.
• [46]Sanz-Ruiz R, Ibanes EG, Arrranz AV, Santos MEF, Fernandez PLS, Fernandez-Aviles F: Phases I-III clinical trials using adult stem cells.Stem cells Intern 2010, 1¿12.
• [47]Tara M, Herrick RPM: Tapping the potential of fixed-dose combinations. Nat Rev Drug Disc 2007, 6:513-514.
• [48]Mocanu MM, Yellon DM: PTEN, the Achilles¿ heel of myocardial ischemia/reperfusion injury? Br J Pharmacol 2007, 150:833-838.
• [49]Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y: Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 2006, 291:1158-1169.
• [50]Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Barry FU, Yochai Birnbaum MD: Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with lowdose atorvastatin. Cardiovasc Drugs Ther 2006, 20:27-36.
• [51]Foubert P, Matrone G, Souttou B, Lere¿-De¿An C, Barateau V, Plouet J, Le Ricousse-Roussanne S, Levy BI, Silvestre J, Tobelem G: Coadministration of endothelial and smooth muscle progenitor cells enhances the efficiency of proangiogenic cell-based therapy. Circ Res 2008, 103:751-760.
• [52]Yamahara K, Sone M, Itoh H, Yamashita JK, Yurugi-Kobayashi T, Homma K, Chao T, Miyashita K, Park K, Oyamada N, Sawada N, Taura D, Fukunaga Y, Tamura N, Nakao K: Augmentation of neovascularizaiton in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One 2008, 3:e1666.
• [53]Kanathezhath B, Walters MC: Umbilical cord blood transplantation for thalassemia major. Hematol Oncol Clin North Am 2010, 24:1165-1177.
• [54]Madureira AB, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM, Picardi A, Woolfrey A, Chan KW, Socie G, Vora A, Bertrand Y, Sales-Bonfim CM, Gluckman E, Niemeyer C, Rocha V: Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia 2011, 25:449-454.
• [55]Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ: Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: Umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplan 2012, 47:494-498.
• [56]Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG: Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplan 2011, 17:1327-1334.
• [57]Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, Martens AC, Brinon JG, Miguel JFS, del Canizo MC, Sanchez-Guijo F: Effects of MSC coadministration and route of delivery on cord blood hematopiectic stem cell engraftment. Cell Transplan 2013, 22:1171-1183.
• [58]Kirpatovskii VI, Kazachenko V, Yanenko EK, Kovalenko EA, Golovanov SA: Enhancement of the anti-ischemic kidney resistance by adaptive hypoxic preconditioning and drug therapy. Bullet Exp Biol Med 1999, 127:278-281.
• [59]Kato T, Yoshimoto N: Ischemic preconditioning and outcomes after angioplasty: effects of drug therapy. Drugs 2003, 63:133-138.
• [60]Diaz Z, Assaraf MI, Miller WHJ, Schipper HM: Astroglial cytoprotection by erythropoietinpre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem 2005, 93:392-402.
• [61]Gidday JM: Pharmacologic preconditioning: translating the promise. Transl Stroke Res 2010, 1:19-30.
• [62]Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, Zacharowski K: Preconditioning by toll-like receptor 2 agonist pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med 2010, 38:903-909.
• [63]McNally SJ, Harrison EM, Wigmore SJ: Ethical considerations in the application of preconditioning to solid organ transplantation. J Med Ethics 2005, 31:631-634.
• [64]Haider HK, Ashraf M: Preconditioning and stem cell survival. J Cardiovasc Transl Res 2010, 3:89-102.
• [65]Cai H, Zhang Z, Yang GY: Preconditioned Stem Cells: a Promising Strategy for Cell-Based Ischemic Stroke Therapy. Curr Drug Targets 2014, 15(8):771-779.
• [66]Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4(Suppl 6):581.
• [67]Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H, Nowakowska B, Phoolchund A, Lay K, Ramasamy TS, Cananzi M, Nettersheim D, Sullivan M, Frost J, Moore G, Vermeesch JR, Fisk NM, Thrasher AJ, Atala A, Adjaye J, Schorle H, Coppi PD, Guillot PV: Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Therapy 2012, 20(10):1953-1967.
• [68]Haider KH, Ashraf M: Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci 2012, 111:323-356.
• [69]Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K, Sasai Y: A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotech 2007, 25:681-686.
• [70]Ramasamy TS, Yu JSL, Selden C, Hodgson H, Cui W: Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality. Tissue Eng Part A 2013, 19(Suppl 3¿4):360-367.
• [71]Jeremy LH, Yue W, Abarbanell MA, Brent RW, Jiangning T, Daniel RM: Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell mediated cardioprotection. Shock 2010, 33:24-30.
• [72]Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J, Wei L: Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008, 135:799-808.
• [73]Pasha Z, Wang Y, Sheikh R, Zhang D, Tiemin Zhao T, Ashraf M: Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008, 77:134-142.
• [74]Carriere A, Ebrahimian TG, Dehez S, Auge N, Joffre C, Andre M, Arnal S, Duriez M, Barreau C, Arnaud E, Fernandez Y, Planat-Benard V, Lévy B, Pénicaud L, Silvestre JS, Casteilla L: Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. Arterioscler Thromb Vasc Biol 2009, 29:1093-1099.
• [75]Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P: Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-Trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacolo Exp Ther 2009, 329:543-550.
• [76]Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ: Therapeutic cell engineering using surface-conjugated synthetic nanoparticles. Nat Med 2010, 16:1035-1041.
• [77]Mamidi MK, Pal R, Govindasamy V, Zakaria Z, Bhonde R: Treat the graft to improve the regeneration ability of the host. Med Hyp 2011, 76:599-601.
• [78]Yu SP, Wei Z, Wei L: Preconditioning strategy in stem cell transplantation therapy. Transl Stroke Res 2013, 4:76-88.
• [79]Kim SW, Kim HW, Huang W, Okada M, Welge JA, Wang Y, Ashraf M: Cardiac stem cells with electrical stimulation improve ischaemic heart function through regulation of connective tissue growth factor and miR-378. Cardiovascular Res 2013, 100(Suppl 2):241-251.
• [80]Jaderstad J, Brismar H, Herlenius E: Hypoxia preconditioning increases gap-junctional graft and host communication. Neuro-report 2010, 21:1126-1132.
• [81]Lau TT, Wang DA: Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther 2011, 11(Suppl 2):189-197.
• [82]Jones J, Marian D, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA: CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res 2007, 313(Suppl 19):4051-4065.
• [83]Jenkins AJ, Cone EJ: Pharmacokinetics: drug absorption, distribution and elimination. In Drug Abuse Handbook. Edited by Karch SB. Boca Rato¿n, FL, CRC Press; 1998:151-201.
• [84]Brunskill SJ, Hyde CJ, Doree CJ, Suzanne M, Watt SM, Martin-Rendon E: Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrowderived cell therapy for ischaemic heart disease. Europ J Heart Fail 2009, 11:887-896.
• [85]Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M, Frassoni F, Dal Canton A, Dionigi P, Alessiani M: Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? Transplant Proc 2010, 42:1336-1340.
• [86]Fernandez-Aviles F, San Roman JA, Garcia-Frade J, Fernandez ME, Penarrubia MJ, de laFuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 2004, 95:742-748.
• [87]Ott HC, McCue J, Taylor DA: Cell-based cardiovascular repair-the hurdles and the opportunities. Basic Res Cardiol 2005, 100:504-517.
• [88]Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE: Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006, 97:823-829.
• [89]Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T: Catheterbased delivery of cells to the heart. Nat Clin Pract 2006, 3:S57-S64.
• [90]Dimmeler S, Burchfield J, Zeiher AM: Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008, 28:208-216.
• [91]Willing E, Garbuzova-Davis S, Sanberg PR, Saporta S: Routes of stem cell administration in the adult rodent. Methods Mol Biol 2008, 438:383-401.
• [92]Cindy TJ, Velthoven V, kaVelaars A, van Bel F, Heijnen CJ: Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 2010, 68:419-422.
• [93]Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, Katakowski M, Zhang LJ, Lu M, Janakiraman N, Chopp M: Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002, 59:514-523.
• [94]Sykova E, Homola A, Mazanec R, Lachmann H, Konradova SL, Kobylka P, Pádr R, Neuwirth J, Komrska V, Vávra V, Stulík J, Bojar M: Autologous bone marrow transplantation in patients with sub acute and chronic spinal cord injury. Cell Transplant 2006, 15:675-687.
• [95]Paul C, Samdani AF, Betz RR, Fischer I, Birgit Neuhuber B: Grafting of human bone marrow stromal cells into spinal cord injury: A comparison of delivery methods. Spine (Phila Pa 1976) 2009, 34:328-334.
• [96]Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913-1918.
• [97]Moscoso I, Barallobre J, de Ilarduya ÓM, Añón P, Fraga M, Calviño R, Aldama G, Doménech N: Analysis of different routes of administration of heterologous 5-Azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. Transplant Proc 2009, 41:2273-2275.
• [98]Rigol MR, Solanes N, Farre J, Roura S, Roque M, Berruezo A, Bellera N, Novensà L, Tamborero D, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramírez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayés-Genís A, Heras M: Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration. J Card Fail 2010, 16:357-366.
• [99]Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011, 18:488-495.
• [100]Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F: Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant 2008, 17:1277-1293.
• [101]Strauer BE, Kornowski R: Stem cell therapy in perspective. Circulation 2003, 107:929-934.
• [102]Johanson CE, Uhlenhuth EH: Drug preferences in humans. Fed Proc 1982, 41:228-233.
• [103]de wit H, Uhlenhuth EH, Johanson CE: Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 1986, 16:341-360.
• [104]Thurmann PA: Gender-related differences in pharmacokinetics and pharmocodynamics. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005, 48:536-540.
• [105]Soldin OP, Mattison DR: Sex differnces in pharmacokinetics and pharmocodynamics. Clin Pharmocokinet 2009, 48:143-157.
• [106]Hughes DA, Aronson JK: A systematic review and empirical analysis of the relation between dose and duration of drug action. J Clin Pharmacol 2010, 50:17-26.
• [107]Varrassi G, Marinangeli F, Agro F, Aloe L, De Nicola A, Giunta F, Ischia S, Ballabio M, Stefanini S: A double-blinded evaluation of propacetamol versus ketorolac in combination with patient controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg 1999, 88:611-616.
• [108]Struys MMRF, Sahinovic M, Lichtenbelt BJ, Vereecke HEM, Absalom AR: Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. Brit J Anaesth 2011, 107:1-10.
• [109]Bartmann C, Rohde E, Schallmoser K, Pürstner P, Lanzer G, Linkesch W, Strunk D: Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007, 47:1426-1435.
• [110]Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A: Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010, 227:185-189.
• [111]Kishk NA, Gabr H, Hamdy S, Afifi L, Abokresha N, Mahmoud H, Wafaie A, Bilal D: Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair 2010, 24:702-708.
• [112]Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69:1423-1429.
• [113]Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction. J Am Coll Cardiol 2009, 54(24):2277-2286.
• [114]Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Brynes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A: Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
• [115][http://www.medpagetoday.com/MeetingCoverage/ANA/42288] webcite Geber J: Meeting coverage ¿ALS Stem Cell Therapy: Too Soon to Tell¿. []
• [116][http://clinicaltrials.gov/show/NCT01609283] webcite Clinical Trials of U.S. National Institutes of Health. []
• [117]Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW: A double-blind placebo- controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke 2014, 9(3):381-386.
• [118][http://clinicaltrials.gov/ct2/show/NCT01144962] webcite Clinical Trials of U.S. National Institutes of Health. []
• [119]Mason C, Mason J, Culme-Seymour EJ, Bonfiglio GA, Reeve BC: Cell Therapy Companies Make Strong Progress from October 2012 to March 2013 Amid Mixed Stock Market Sentiment. Cell Stem Cell 2013, 12:644-647.
• [120]Ma T: Mesenchymal stem cells; cell therapy; cell expansion and processing. World J of Stem Cells 2010, 2:13-17.
• [121]Ledford KJ, Zeigler F, Bartel RL: Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res Ther 2013, 4:134.
• [122]Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379(9817):713-720.
• [123]Vaes B, Van¿t Hof W, Deans RJ, Pinxteren J: Application of MultiStem allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012, 3:345.
• [124][http://www.biotimeinc.com/] webcite BioTime. []
• [125][http://www.cytomedix.com/] webcite Cytomedix regenerative therapies. []
• [126][http://www.cytori.com/Home.aspx] webcite Cytori. []
• [127]Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010, 363:411-422.
• [128][http://www.fibrocellscience.com/about/about-fibrocell/] webcite Fibrocell Science. []
• [129][http://www.imuc.com/technology] webcite Immunocellular Therapeutics. []
• [130][http://www.jpte.co.jp/english/business/Regenerative/index.html] webcite J-TEC Japan Tissue Engineering. []
• [131][http://www.medi-post.com/am_1.asp] webcite Medipost. []
• [132][http://www.mesoblast.com/about-us/company-overview] webcite Mesoblast: The regenerative medicine company. []
• [133][http://www.neostem.com/about/overview/] webcite Neostem. []
• [134][http://www.neuralstem.com/cell-therapy] webcite Neuralstem Cell therapy. []
• [135][http://www.nwbio.com/] webcite Northwest Biotherapeutics. []
• [136][http://www.osiris.com/biosurgery.php] webcite Osiris. []
• [137][http://www.pharmicell.com/eng/index.asp] webcite Pharmicell. []
• [138][http://www.pluristem.com/index.php/about2.html] webcite Pluristem Therapeutics. []
• [139][http://www.stemcellsinc.com/About-Us/Overview.htm] webcite Stem Cells. []
• [140][http://www.tigenix.com/en/page/4/company] webcite Tigenix. []
• [141]Murphy MB, Moncivais K, Caplan AI: Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013, 45(e54):1-16.
• [142]Haack-Sørensen M, Friis T, Mathiasen AB, Jørgensen E, Hansen L, Dickmeiss E, Ekblond A, Kastrup J: Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant 2013, 22:521-528.
• [143]Chen L, Tredget EE, Wu PYG, Wu Y: Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3:e1886.
• [144]Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayer D, Carson P: Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007, 13:1299-1312.
• [145]Bey E, Prat M, Duhamel P, Benderitter M, Brachet M, Trompier F, Battaglini P, Ernoul I, Boutin L, Gourven M, Tissedre F, Crea S, Mansour CA, de Revel T, Carsin H, Gourmelon P, Lataillade JJ: Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. Wound Repair Regen 2010, 18:50-58.
• [146]Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M: Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2014, 494:100-105.
• [147]Charron D: Allogenicity & immunogenicity in regenerative stem cell therapy. Indian J Med Res 2013, 138:749-754.
• [148]Abbasalizadeh S, Baharvand H: Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotech Adv 2013, 31(8):1600-1623.
• [149]Ma Q, Lu AYH: Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol Rev 2011, 63:437-459.